Back to Search Start Over

Oseltamivir Treatment for Influenza During the Flu Season of 2018–2019: A Longitudinal Study

Authors :
Xiao-Guang Li
Jing Chen
Wei Wang
Fei Lin
Lu Li
Jing-Jin Liang
Zhong-Hua Deng
Bi-Ying Zhang
Ying Jia
Yuan-Bo Su
Yong-Feng Kang
Juan Du
Ya-Qiong Liu
Jie Xu
Qing-Bin Lu
Source :
Frontiers in Microbiology, Vol 13 (2022)
Publication Year :
2022
Publisher :
Frontiers Media S.A., 2022.

Abstract

BackgroundOseltamivir resistance in influenza virus (IFV) has been of widespread concern. An increase in the frequency of viruses with reduced inhibition was observed. Whether oseltamivir is effective is uncertain. We conducted this study to understand the real-world situation in northern China and the clinical efficacy for patients with IFV infection after the use of oseltamivir.MethodsThe longitudinal study was performed on influenza-like illness (ILI) cases in a tertiary general hospital in Beijing, China during the flu season of 2018–2019. All ILI cases (≥18 years) were recruited into the study. We analyzed the effect of the oseltamivir therapy on the number of clinic visits, hospitalization frequency, and the duration of fever and cough.ResultsA total of 689 ILI patients were recruited in this study with 355 in the oseltamivir therapy group and 334 in the supportive therapy group. Among the ILI patients, 388 patients were detected for IFV infection (364 IFV-A and 24 IFV-B) and divided into two groups with or without the oseltamivir therapy (302 vs. 86). There were no significant differences in the basic characteristics between the oseltamivir and supportive therapy groups in the ILI patients or in the IFV positive patients (all p

Details

Language :
English
ISSN :
1664302X
Volume :
13
Database :
Directory of Open Access Journals
Journal :
Frontiers in Microbiology
Publication Type :
Academic Journal
Accession number :
edsdoj.4bc5e8e55c94a768aae21af99aafb55
Document Type :
article
Full Text :
https://doi.org/10.3389/fmicb.2022.865001